肿瘤微环境（TME）由肿瘤细胞、免疫细胞和基质细胞共同构成，每个细胞组分之间的相互作用对肿瘤发生发展起着关键影响。TME中免疫细胞和基质细胞通过引起细胞毒性或炎症反应来对抗肿瘤细胞，但它们也通过一系列免疫调节机制参与肿瘤逃逸。既往抗淋巴瘤的治疗主要靶向恶性细胞本身，但随着免疫检查点抑制剂、双特异性抗体和嵌合抗原受体T细胞等免疫治疗的临床应用，消除TME对肿瘤细胞的保护作用也越发得到重视。借助质谱流式分析仪（CyTOF）和成像质谱流式细胞术（IMC）高通量和高维数据的解析能力，大样本量解析淋巴瘤TME构成已经成为可能。 The tumor microenvironment (TME) is comprised of tumor cells, immune cells and stromal cells, moreover the intricate interactions among these cellular components play a vital role in tumor initiation and progression. Within the TME, immune cells and stromal cells engage in cytotoxic or inflammatory responses to counteract tumor cells, but they employ a range of immune regulatory mechanisms to facilitate tumor evasion. Previous treatments for lymphoma mainly targeted malignant cells themselves. However, with the clinical application of immune checkpoint inhibitors, bispecific antibodies and chimeric antigen receptor T-cell therapy, the elimination of TME-mediated tumor protection has gained increasing attention. By harnessing the high-throughput and multi-dimensional analytical capabilities of mass cytometry (CyTOF) and imaging mass cytometry (IMC), it has become feasible to systematically analyze the composition of the lymphoma TME using large-scale samples.
The application of mass spectrometry flow cytometry and related imaging techniques in the study of the lymphoma microenvironment
The tumor microenvironment (TME) is comprised of tumor cells, immune cells and stromal cells, moreover the intricate interactions among these cellular components play a vital role in tumor initiation and progression. Within the TME, immune cells and stromal cells engage in cytotoxic or inflammatory responses to counteract tumor cells, but they employ a range of immune regulatory mechanisms to facilitate tumor evasion. Previous treatments for lymphoma mainly targeted malignant cells themselves. However, with the clinical application of immune checkpoint inhibitors, bispecific antibodies and chimeric antigen receptor T-cell therapy, the elimination of TME-mediated tumor protection has gained increasing attention. By harnessing the high-throughput and multi-dimensional analytical capabilities of mass cytometry (CyTOF) and imaging mass cytometry (IMC), it has become feasible to systematically analyze the composition of the lymphoma TME using large-scale samples.
万方数据
